ArticleFrontiers in pharmacology2026
Glucosamine/platelet-rich plasma/bone marrow MSC-loaded GelMA hydrogel supports cartilage endplate repair in mice and is associated with reduced inflammation- and oxidative stress-related readouts.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In this study, we developed a gelatin methacryloyl (GelMA) hydrogel composite for the simultaneous delivery of glucosamine (GlcN), platelet-rich plasma (PRP), and bone marrow-derived mesenchymal stem cells (BMMSCs). We systematically investigated its effects on cartilage endplate (CEP) cell behavior, inflammation, and oxidative stress, and evaluated its reparative efficacy in a murine caudal CEP injury model. Methods: GlcN/PRP/BMMSC@GelMA was fabricated and comprehensively characterized in terms of its microarchitecture, compressive and rheological properties, enzymatic degradability, swelling, and the sustained release profile of GlcN and platelet-derived growth factor (PDGF). Additionally, primary CEP cells were treated with either GelMA or GlcN/PRP/BMMSC@GelMA to evaluate cell viability, proliferation, apoptosis, and the expression of chondrogenic markers (COL2A1, ACAN, and SOX9) using RT-qPCR and Western blot. Under lipopolysaccharide (LPS) challenge, cytokines (IL-1β, IL-6, TNF-α, IL-10) were quantified using ELISA. Under H Results: The composite formed a stable three-dimensional network with higher elastic and storage moduli than GelMA alone and supported the sustained release of GlcN and PDGF. The composite also improved CEP cell viability and proliferation, reduced apoptosis, and increased the expression of collagen II, aggrecan, and SOX9. In addition, it reduced LPS-induced inflammatory cytokines and mitigated H Conclusion: GlcN/PRP/BMMSC@GelMA showed favorable
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.